Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What's The Price For Marketing A DESI Drug? Solvay Settles Estratest Class Action for $30 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Settlement in California follows claim that the hormone replacement therapy was in fact unapproved; a similar action is pending in Minnesota.

You may also be interested in...



Product Liability Forecast: More Suits, Smaller Scale

More than 20 drugs are the subject of multidistrict product liability litigation, but none of the pending cases approach the scope of past lawsuits against Merck’s Vioxx and Lilly’s Zyprexa. That may be one silver lining for Big Pharma as the blockbuster era draws to a close.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says

Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel